The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
PHTHALAZINONE AND RELATED ANALOGS AS SIRTUIN MODULATORS
申请人:Vu Chi B.
公开号:US20130190309A1
公开(公告)日:2013-07-25
Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.
FUNCTIONALIZED PYRROLIDINES AND USE THEREOF AS IAP INHIBITORS
申请人:Laurent Alain
公开号:US20120009141A1
公开(公告)日:2012-01-12
A compound of Formula 1: or a salt thereof, and methods for the use thereof, especially as an IAP inhibitor, as well as related compounds, compositions, and methods.
Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I:
or a salt thereof, in which R
1
, R
2
, R
100
, R
200
, A, A
1
, B, B
1
, BG, n, Q and Q
1
are substituents described. Also disclosed is the use of compounds of Formula 1 to treat proliferative disorders.
ISOINDOLINONE AND RELATED ANALOGS AS SIRTUIN MODULATORS
申请人:Vu Chi B.
公开号:US20110319411A1
公开(公告)日:2011-12-29
Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.